158 related articles for article (PubMed ID: 21438066)
1. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
Gan CP; Hamid S; Hor SY; Zain RB; Ismail SM; Wan Mustafa WM; Teo SH; Saunders N; Cheong SC
Head Neck; 2012 Mar; 34(3):344-53. PubMed ID: 21438066
[TBL] [Abstract][Full Text] [Related]
2. Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Patties I; Kortmann RD; Menzel F; Glasow A
J Exp Clin Cancer Res; 2016 Jun; 35(1):94. PubMed ID: 27317342
[TBL] [Abstract][Full Text] [Related]
3. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Mongan NP; Gudas LJ
Mol Cancer Ther; 2005 Mar; 4(3):477-86. PubMed ID: 15767557
[TBL] [Abstract][Full Text] [Related]
5. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.
Whang YM; Choi EJ; Seo JH; Kim JS; Yoo YD; Kim YH
Cancer Chemother Pharmacol; 2005 Nov; 56(5):543-55. PubMed ID: 15959780
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
Lee SH; Nam HJ; Kang HJ; Samuels TL; Johnston N; Lim YC
Oncol Rep; 2015 Oct; 34(4):2065-71. PubMed ID: 26239260
[TBL] [Abstract][Full Text] [Related]
7. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enzenhofer E; Kadletz L; Stanisz I; Kotowski U; Seemann R; Schmid R; Thurnher D; Heiduschka G
Head Neck; 2017 May; 39(5):900-907. PubMed ID: 28170128
[TBL] [Abstract][Full Text] [Related]
8. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
9. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
11. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
12. A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.
Alhazzazi TY; Kamarajan P; Xu Y; Ai T; Chen L; Verdin E; Kapila YL
Anticancer Res; 2016 Jan; 36(1):49-60. PubMed ID: 26722027
[TBL] [Abstract][Full Text] [Related]
13. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines.
Patties I; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2013 May; 32(1):27. PubMed ID: 23672687
[TBL] [Abstract][Full Text] [Related]
15. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
De Schutter H; Kimpe M; Isebaert S; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid and all trans retinoic acid differentially induce megakaryopoiesis and platelet-like particle formation from the megakaryoblastic cell line MEG-01.
Schweinfurth N; Hohmann S; Deuschle M; Lederbogen F; Schloss P
Platelets; 2010; 21(8):648-57. PubMed ID: 20942599
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines.
Atri S; Nasoohi N; Hodjat M
Curr Mol Pharmacol; 2021; 14(1):60-67. PubMed ID: 32394848
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids.
Wan H; Oridate N; Lotan D; Hong WK; Lotan R
Cancer Res; 1999 Jul; 59(14):3518-26. PubMed ID: 10416619
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A
Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
